Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
AssigneePureTech LYT 100, Inc.
InventorsMichael C. Chen, Eric Elenko, Camilla S. Graham, Varun Garg
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method of treating interstitial lung disease and other fibrotic-mediated pulmonary diseases or disorders. The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 825 mg to about 2475 mg.
Claims17
A method of treating a fibrotic-mediated pulmonary disease or disorder, comprising administering to a subject in need thereof total daily dose from about 825 to about 2475 mg of a deuterium-enriched pirfenidone having the structure:
- wherein the fibrotic-mediated pulmonary disease or disorder is treated in the subject.
The method according to claim 14, wherein the ILD is an exposure-related ILD, a drug-induced ILD, an autoimmune interstitial lung disease, unclassifiable interstitial lung disease (uILD), progressive fibrotic interstitial lung disease (pfILD), respiratory bronchiolitis-ILD (RB-ILD), a connective tissue disease-related ILD (CTD-ILD), rheumatoid arthritis (RA-ILD), systemic sclerosis (SSc-ILD), mixed connective tissue disease-ILD, scleroderma related ILD, or ILD related to chronic sarcoidosis.
The method according to claim 14 or 15, wherein the ILD is a progressive fibrosing ILD (PF-ILD).
Dependencies are inferred from the claim text.